Posted On: 08/30/2015 10:36:51 AM
Post# of 72447
Great news, if U of Bologna review board met in July, given that Italy basically shuts down in August, that means we should get some news there in a few weeks.
For those who don't know, U of Bologna is one of Europe's leading research institutions. They want to do a study on Kevetrin, combining it with other cancer drugs to see if it increases survival. Although there is some anecdotal evidence that Kevetrin has efficacy as a single agent (like the guy with stage 4 thymus cancer who has survived for 11 months and is still walking the earth, and the ovarian cancer patient who had a metastatic spleen lesion "disappear" except for a little scar tissue) -- nevertheless CTIX has always said that using it in conjunction with more traditional therapies was the goal.
And, the U of Bologna is paying for the study -- all we have to do is supply them with the Kevetrin.
For those who don't know, U of Bologna is one of Europe's leading research institutions. They want to do a study on Kevetrin, combining it with other cancer drugs to see if it increases survival. Although there is some anecdotal evidence that Kevetrin has efficacy as a single agent (like the guy with stage 4 thymus cancer who has survived for 11 months and is still walking the earth, and the ovarian cancer patient who had a metastatic spleen lesion "disappear" except for a little scar tissue) -- nevertheless CTIX has always said that using it in conjunction with more traditional therapies was the goal.
And, the U of Bologna is paying for the study -- all we have to do is supply them with the Kevetrin.
(0)
(0)
